http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2537183-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e93cd2b8ded184f2271f2d0ca1782fa |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-205 |
| filingDate | 2012-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_129e8abd3b739f710e66c7a1ae059477 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ce8b90514e4861de1eba4d3bab5acb7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2048e8a3f14778c70892d956fce15d3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aab5a15ea8b062ceb092834bb5144d6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ad51ec89b4e88f609421b6ce2d46e37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7446f96fa8f7d77f035321c63ef06a9f |
| publicationDate | 2014-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2537183-C2 |
| titleOfInvention | Method for preparing inactivated antirabic vaccine in frameless cell growth and virus replication in short-term culture cycle |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to veterinary biotechnology, namely a method for preparing an antirabic vaccine. That is ensured by using the cell sub-line VNK-21/13-02 by growing them with using a frameless technique in a special medium for creating the suspension environment, herewith using the Hanks' solution for the suspension culture with added bovine blood serum examined for the absence of rabies virus antibodies and growth properties in a concentration of 2.5%, D-glucose (1.0 g/l), D-fructose (1.0 g/l), l-glutamine (0.3 g/l), bovine enzymatic muscular hydrolysate (0.35% at a dry substance basis), l-arginine, l-methionine, l-cystine, myoinositol and water-soluble vitamins according to the Eagle's minimal essential medium (MEM) formulation to the concentration of (2.5-3.0)×10 6 cell/ml. The grown cell culture is infected with the rabies viral strain Schelkovo-51 adapted to this system in a dose of 0.1-1.0 MLD 50 /cells with the incubation procedure performed at a temperature of 37°C for 48-72 hours by using the frameless technique. That is followed by adding a stabilising buffer fixing the pH values within 7.2-7.6; the prepared virus-containing material is inactivated with beta-propiolactone in the final concentration of 0.025% and used to prepare a sorbed or dry vaccine. n EFFECT: using the presented method enables providing higher potency of the product by specific cell density by the moment of infection, an optimum dose of infection and time of the virus replication in the infected cells. n 5 cl, 3 ex, 3 tbl |
| priorityDate | 2012-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.